Evidence map›Paper›PMID 30769923›Full record

ArticleVaccines2019

Comparison of Immune Responses to Different Versions of VLP Associated Stabilized RSV Pre-Fusion F Protein.

Lori M Cullen, Madelyn R Schmidt, Gretel M Torres, Adam A Capoferri, Trudy G Morrison

Open access · goldAbstract read
In one paragraph

Article in Vaccines, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Lori M CullenDepartment of Microbiology and Physiological Systems, University of Massachusetts Medical School, Worcester, MA 01655, USA. Lori.Mcginnes@umassmed.edu.
Madelyn R SchmidtDepartment of Microbiology and Physiological Systems, University of Massachusetts Medical School, Worcester, MA 01655, USA. Madelyn.Schmidt@umassmed.edu.
Gretel M TorresProgram of Immunology and Microbiology, University of Massachusetts Medical School, Worcester, MA 01655, USA. Gretel.M.Torres.GR@dartmouth.edu.
Adam A CapoferriDepartment of Microbiology and Physiological Systems, University of Massachusetts Medical School, Worcester, MA 01655, USA. alongwi2@jhmi.edu.ORCID 0000-0002-6048-2115
Trudy G MorrisonDepartment of Microbiology and Physiological Systems, University of Massachusetts Medical School, Worcester, MA 01655, USA. trudy.morrison@umassmed.edu.
University of Massachusetts Chan Medical School · US

Funding

Development of VLP vaccine for RSVR44AI109926 · NIAID · SIGMOVIR BIOSYSTEMS, INC. · PI BLANCO, JORGE C · 2019 to 2021
$3.5M
Role of F Protein Conformation in RSV Vaccine EfficacyR56AI114809 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI MORRISON, TRUDY G. · 2016 to 2016
$634k
Development of VPL Vaccine for RSVR41AI109926 · NIAID · SIGMOVIR BIOSYSTEMS, INC. · PI BLANCO, JORGE C · 2014 to 2014
$225k
National Institutes of Health, USA, Hood Foundation AI 114809NIAID NIH HHS R41 AI109926NIAID NIH HHS R44 AI109926NIAID NIH HHS R56 AI114809
6 · The paper itself

Abstract

Efforts to develop a vaccine for respiratory syncytial virus (RSV) have primarily focused on the RSV fusion protein. The pre-fusion conformation of this protein induces the most potent neutralizing antibodies and is the focus of recent efforts in vaccine development. Following the first identification of mutations in the RSV F protein (DS-Cav1 mutant protein) that stabilized the pre-fusion conformation, other mutant stabilized pre-fusion F proteins have been described. To determine if there are differences in alternate versions of stabilized pre-fusion F proteins, we explored the use, as vaccine candidates, of virus-like particles (VLPs) containing five different pre-fusion F proteins, including the DS-Cav1 protein. The expression of these five pre-F proteins, their assembly into VLPs, their pre-fusion conformation stability in VLPs, their reactivity with anti-F monoclonal antibodies, and their induction of immune responses after the immunization of mice, were characterized, comparing VLPs containing the DS-Cav1 pre-F protein with VLPs containing four alternative pre-fusion F proteins. The concentrations of anti-F IgG induced by each VLP that blocked the binding of prototype monoclonal antibodies using two different soluble pre-fusion F proteins as targets were measured. Our results indicate that both the conformation and immunogenicity of alternative VLP associated stabilized pre-fusion RSV F proteins are different from those of DS-Cav1 VLPs.

Indexed as

F proteinimmune responsesrespiratory syncytial virusvaccineVLPs

Identifiers

PMID30769923
PMCPMC6466353
OpenAlexW2913722064

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.